Nanosphere, Inc. (NASDAQ:NSPH), a company enhancing medicine through targeted and flexible molecular diagnostics, announced that new clinical data for the Verigene® Gram-Positive (BC-GP) and Gram-Negative (BC-GN) Blood Culture Tests for rapid sepsis diagnostics were presented during Sepsis Awareness Month at the 55th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), held last week in San Diego, CA.

Four of the five studies presented at ICAAC 2015 included an analysis of the impact of Verigene BC-GP and/or BC-GN on patient outcomes. Results from each of these studies showed a reduction in patient length-of-stay in the hospital or ICU, reduction in the time to organism identification, and reduction in time to optimal therapy.

Verigene studies presented at ICAAC included:

Shares of Nanosphere closed yesterday at $2.10. NSPH has a 1-year high of $25.40 and a 1-year low of $2.02. The stock’s 50-day moving average is $2.48 and its 200-day moving average is $3.51.

On the ratings front, Nanosphere has been the subject of a number of recent research reports. In a report issued on September 8, Chardan analyst Keay Nakae initiated coverage with a Buy rating on NSPH and a price target of $3.30, which implies an upside of 57.1% from current levels. Separately, on August 12, Piper Jaffray’s William Quirk maintained a Hold rating on the stock and has a price target of $2.60.

According to, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Keay Nakae and William Quirk have a total average return of -22.0% and 4.4% respectively. Nakae has a success rate of 25.0% and is ranked #3648 out of 3768 analysts, while Quirk has a success rate of 57.1% and is ranked #1407.

Nanosphere Inc develops, manufactures and markets molecular diagnostics platform, the Verigene System, which enables sensitive genomic and protein testing on a single platform.